PTL 03001Alternative Names: Deslorelin - Peptech
Latest Information Update: 22 Mar 2007
At a glance
- Originator Peptech
- Mechanism of Action Gonadotropin releasing hormone stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 17 Jul 2001 This compound is still in active development
- 18 Dec 1997 Preclinical development for Prostate cancer in Australia (Intralesional)